Abstract
Aspirin is not effective in the primary prevention of stroke. Patients with TIA or ischemic stroke carry a risk of recurrent stroke between 5 and 20% per year. In patients with TIA or ischemic stroke of noncardiac origin antiplatelet drugs are able to decrease the risk of stroke by 11-15% and the risk of stroke, MI and vascular death by 15-22%. Aspirin is the most widely used drug. It is affordable and effective. Low doses of 50-325 mg aspirin are as effective as high doses and cause less gastrointestinal side effects. Severe bleeding complications are dose-dependent. The combination of aspirin with slow release dipyridamole is superior to aspirin alone for stroke prevention. Clopidgrel is superior to aspirin in patients at high risk of recurrence. The combination of aspirin plus clopidogrel is not more effective than clopidogrel alone but carries a higher bleeding risk. None of the antiplatelet agents is able to reduce mortality.
Keywords: myocardial infarction, dipyridamole, Hypertension, aspirin, transient ischemic attacks
Current Pharmaceutical Design
Title: Primary and Secondary Stroke Prevention with Antiplatelet Drugs
Volume: 12 Issue: 10
Author(s): Hans-Christoph Diener
Affiliation:
Keywords: myocardial infarction, dipyridamole, Hypertension, aspirin, transient ischemic attacks
Abstract: Aspirin is not effective in the primary prevention of stroke. Patients with TIA or ischemic stroke carry a risk of recurrent stroke between 5 and 20% per year. In patients with TIA or ischemic stroke of noncardiac origin antiplatelet drugs are able to decrease the risk of stroke by 11-15% and the risk of stroke, MI and vascular death by 15-22%. Aspirin is the most widely used drug. It is affordable and effective. Low doses of 50-325 mg aspirin are as effective as high doses and cause less gastrointestinal side effects. Severe bleeding complications are dose-dependent. The combination of aspirin with slow release dipyridamole is superior to aspirin alone for stroke prevention. Clopidgrel is superior to aspirin in patients at high risk of recurrence. The combination of aspirin plus clopidogrel is not more effective than clopidogrel alone but carries a higher bleeding risk. None of the antiplatelet agents is able to reduce mortality.
Export Options
About this article
Cite this article as:
Diener Hans-Christoph, Primary and Secondary Stroke Prevention with Antiplatelet Drugs, Current Pharmaceutical Design 2006; 12(10) . https://dx.doi.org/10.2174/138161206776361273
DOI https://dx.doi.org/10.2174/138161206776361273 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Chemometric Assisted Simultaneous Analysis of Verapamil Hydrochloride, Gliclazide and Simvastatin in Bulk Drug and Fixed Dose Combinatinos (polypill) - A Futuristic Approach
Current Analytical Chemistry Cervical Cancer Diagnosis: Insights into Biochemical Biomarkers and Imaging Techniques
Combinatorial Chemistry & High Throughput Screening Antiplatelet and Antithrombotic Therapy After Patent Foramen Oval and Atrial Septal Defect Closure
Current Pharmaceutical Design Developing New Anti-Arrhythmics: Clues from the Molecular Basis of Cardiac Ryanodine Receptor (RyR2) Ca2+-Release Channel Dysfunction
Current Pharmaceutical Design Mining the Genome for Susceptibility to Complex Neurological Disorders
Current Molecular Medicine Vitamins B1, B2, B3 and B9 – Occurrence, Biosynthesis Pathways and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry Lipids in the Diet and the Fatty Acid Profile in Beef: A Review and Recent Patents on the Topic
Recent Patents on Food, Nutrition & Agriculture Cardiovascular Imaging for Guiding Interventional Therapy in Structural Heart Diseases
Current Medical Imaging Sterol 14α-Demethylase from Trypanosomatidae Parasites as a Promising Target for Designing New Antiparasitic Agents
Current Topics in Medicinal Chemistry Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice
Current Pharmaceutical Biotechnology Systems Biology of Apoptosis and Survival: Implications for Drug Development
Current Pharmaceutical Design Cardiac Tissue Engineering
Recent Patents on Regenerative Medicine 1h Post-load Blood Glucose in the Identification of Proatherogenic Cardiometabolic Profile in Obesity
Endocrine, Metabolic & Immune Disorders - Drug Targets Proposing a “Lipemic Index” As a Nutritional and Research Tool
Current Vascular Pharmacology Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs
Current Vascular Pharmacology Nutritional Antioxidants Mechanisms of Action, Analyses of Activities and Medical Applications
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Nutritional and Therapeutic Potential of Garlic and Onion (Allium sp.)
Current Nutrition & Food Science Can microRNAs be Biomarkers or Targets for Therapy of Ischemic Coronary Artery Disease in Metabolic Syndrome?
Current Drug Targets Diabetes Mellitus in Saudi Arabia: A Review of the Recent Literature
Current Diabetes Reviews